Meeting
2017 ASCO Annual Meeting
Afatinib in patients with metastatic HER2-mutant lung cancers: An international multicenter study.
Authors
Wei-Chu Victoria Lai
Memorial Sloan Kettering Cancer Center, New York, NY
Wei-Chu Victoria Lai , Louisiane Lebas , Julie Milia , Tristan Alexandra Barnes , Oliver Gautschi , Solange Peters , Roberto Ferrara , Ai Ni , Joshua K. Sabari , Stephen John Clarke , Nick Pavlakis , Charles M. Rudin , Maria E. Arcila , Natasha B. Leighl , Frances A. Shepherd , Mark G. Kris , Julien Mazieres , Bob T. Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9071)
DOI
10.1200/JCO.2017.35.15_suppl.9071
Abstract #
9071
Poster Bd #
397
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Mutational analysis of rare insertions and deletions in exon 18 and 19 of HER2 in Chinese patients with different cancer types.
First Author: Jianwen Qin
Poster
2018 ASCO Annual Meeting
An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.
First Author: Lore Decoster
Poster
2012 ASCO Annual Meeting
First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers.
First Author: Mark G. Kris
Poster
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
First Author: Tarek Mohamed Ahmed Abdel-Fatah